Explore the dynamic landscape of ovarian cancer with our latest video and join us on a journey through the current trends and groundbreaking innovations in diagnosis, treatments, and patient care that are reshaping the future of ovarian cancer management.
Hypertension, commonly known as high blood pressure, affects millions of people worldwide and poses a significant health risk. In the quest for innovative solutions, the biotech industry is constantly evolving. In this video, we dive into the realm of hypertension to explore the latest trends, breakthroughs, and treatments that are revolutionizing the way we understand...
We are thrilled to extend our heartfelt appreciation and gratitude to our Evergrowth Friends and Family who attended the Evergrowth BioHealthcare Capital 2023 Investor Presentation held last December 27, 2023 at Safety Harbor Resort and Spa, Florida. Your attendance not only marked a significant milestone for us but also played a pivotal role in making...
On December 5, 2023, the Abrahamic Business Circle Investors Roundtable held in the vibrant city of Dubai brought together some of the brightest minds in the business world. Among the distinguished attendees were Dr. Harvey Tran, M.D., M.S., Dr. Linh Nguyen, and Mr. Anton Andonov, esteemed members of the leadership team at Evergrowth Biohealthcare Capital....
Join us for the much-anticipated Annual 2023 Shareholders Meeting in the vibrant setting of Florida on December 27th. This invitation extends to both our valued members and esteemed guests. Immerse yourself in the dynamic atmosphere of the event, where we unveil the latest innovations in the life science sector. Explore firsthand the potential investment opportunities...
The fund’s portfolio division comprises three segments: long-term holdings (60%), power trading positions (10%), and cash (30%). Our high cash position enables us to capture opportunities as they arise. We will deploy much more cash during a bear market to take advantage of deep bargain opportunities. Conversely, we will increase our cash position in a...
Our fund’s stock-picking process involves an integrated assessment of clinical-stage biotech companies, focusing on the lead drug or “Crown Jewel” of the pipeline. This includes evaluating the drug’s Mechanism of Action, Disease Context, and forecasting its chances of passing through clinical studies and gaining FDA approval. It’s important to have a deep understanding of how...
Aligned with Warren Buffett’s wisdom, we are patient with our investments to capture the most upsides. This entails holding stakes in companies for manyyears from their preclinical/clinical phases to early product launch. At that point, we would usually take partial profits to generate more capital and minimize risks while leaving a portion of the shares...
Similar to Warren Buffet, our fund approaches stock buying as investing in a piece of a wonderful business. As such, we would acquire mostly long positions for our investment. There are more upsides to going long while having limited risks. By going long, there is a potential to gain multiple folds on an investment. In...
Our deep specialization in life science equity confers sector expertise and thereby positions us to outperform in this niche. Taking specialization to the next level, we concentrate our investment on the “growth biotech” stocks category. This allows us to capture the tremendous upsides in clinical stage and early product bioequities. Growth stocks tend to outperform...